

CITATION REPORT

List of articles citing

Safety and efficacy of pralsetinib in RET fusionpositive non-small cell lung cancer including as first-line therapy: update from the ARROW trial

DOI: 10.1016/j.annonc.2022.08.002
, 2022, , .

Source: <https://exaly.com/paper-pdf/150295484/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	ARROW: pralsetinib hits target across cancers.		
17	Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). 2022 , 174, 118-124		0
16	Targeting RET alterations in cancer: Recent progress and future directions. 2023 , 181, 103882		0
15	Targeted therapy of RET fusion-positive non-small cell lung cancer. 12,		0
14	Precious Gene: The Application of RET-Altered Inhibitors. 2022 , 27, 8839		0
13	RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. 2023 ,		0
12	Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. 2023 , 15, 179		0
11	Molecular pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.		0
10	Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes. 2023 , 24, 2433		0
9	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 2023 ,		0
8	Targeted Therapy for NonSmall Cell Lung Cancer. 2023 ,		0
7	The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. 2023 , 68, 100958		0
6	Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 2023 , 41, 353-361		0
5	A comprehensive overview of the relationship between RET gene and tumor occurrence. 13,		0
4	RETFusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.		0
3	Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement. 2023 , 100707		0
2	Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?. 2023 , 18, 561-563		0

- 1 Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?. **2023**, 18, 549-551

o